Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
ConclusionsCompared with enalapril, sacubitril/valsartan led to a slower rate of decrease in the eGFR and improved cardiovascular outcomes, even in patients with chronic kidney disease, despite causing a modest increase in UACR.Graphical abstract
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diovan | Enalapril | Heart | Heart Failure | Study | Urology & Nephrology